BioWorld

Nov. 18, 2002

Confirmatory Phase III Prestara Protocol Submitted By Genelabs

Genelabs Technologies Inc. has laid the groundwork for a confirmatory Phase III trial of its lupus drug, Prestara, and said it expects to begin the trial before the end of the year. (BioWorld Today) Read More

NIH Awards Structural GenomiX Authority Over Protein Research

TransForm Pharmaceuticals, Weizmann Institute Align To Develop Better Malaria Drug

SuperGen Receives Approval For Supergeneric Mitozytrex

Medicon Valley Developing R&D Capabilities In Four Key Areas

ViroLogic Plans Cuts While It Raises $10M, Deals With Pfizer

Other News To Note

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 6, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...